论文部分内容阅读
目的:观察PFC方案(紫杉醇联合氟尿嘧啶和顺铂)治疗晚期不能手术或手术未能完全切除及术后复发的食管癌和贲门癌患者的疗效和毒性。方法: 41例患者分别接受PFC方案化疗2~6周期,按WHO标准评价疗效及毒副反应。结果: 41例均可评价,其中完全缓解(CR) 3例7.3%,部分缓解(PR) 18例43.9%,稳定(SD) 15例36.6%,进展(PD) 5例12.2%。中位疾病进展时间为7.9个月,中位生存时间为11.3个月。结论:PFC方案治疗晚期食管贲门癌患者安全有效,毒副反应较轻。
Objective: To observe the efficacy and toxicity of PFC regimen (paclitaxel combined with fluorouracil and cisplatin) in the treatment of patients with esophageal and cardiac cancer who can not be completely resected and who have relapsed after surgery. Methods: Forty-one patients received 2 ~ 6 cycles of PFC regimen respectively. The curative effect and toxicity were evaluated according to WHO criteria. Results: All of the 41 cases were evaluable. Among them, 7.3 were relieved (CR), 43.9% were 18 cases with partial remission (PR), 36.6% were stable with 15 cases of SD and 12.2% were with progressive (PD). The median progression time was 7.9 months and the median survival time was 11.3 months. Conclusion: PFC regimen is safe and effective in the treatment of patients with advanced esophageal and cardiac cancer with mild toxicity.